FHL1 variants cause a wide spectrum of skeletal muscle and cardiac diseases, which can be divided into five main clinical presentations; hypertrophic cardiomyopathy (HC), reducing body myopathy (RBM), and X‐linked myopathy characterized by postural muscle atrophy (XMPMA), scapuloperoneal myopathy (SPM) and EDMD. This evidence concerns the gene FHL1 and heart disorder.